Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature

Grigore,Lavinia   Elena; Ungureanu,Loredana; Bejinariu,Nona; Seceac,Crina; Vasilovici,Alina; Senila,Simona   Corina; Candrea,Elisabeta; Fechete,Oana; Cosgarea,Rodica

doi:10.3892/ol.2018.9738

Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature

Authors:
- Lavinia Elena Grigore
- Loredana Ungureanu
- Nona Bejinariu
- Crina Seceac
- Alina Vasilovici
- Simona Corina Senila
- Elisabeta Candrea
- Oana Fechete
- Rodica Cosgarea
View Affiliations

Affiliations: Department of Dermatology, ‘Iuliu Hațieganu’ University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania, Santomar Oncodiagnostic, 400350 Cluj-Napoca, Romania, Medisprof Cancer Center, 400641 Cluj-Napoca, Romania
Published online on: November 19, 2018 https://doi.org/10.3892/ol.2018.9738
Pages: 4176-4182
Copyright: © Grigore et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is one of the most immunogenic tumors among human neoplasms, with numerous clinical observations of partial or completely regressed tumors. It is an aggressive tumor, with the greatest reported number of somatic mutations, BRAF mutation being the most common one. BRAF mutation is also present in a higher percentage in benign nevi. Complete regression of primary tumor and involution of nevi are, however, rare phenomenon in melanoma that can appear in relation with UV exposure, surgical trauma, target therapy in melanoma, pregnancy or host immune response to an evolving melanoma tumor. We present the case of a 58-year‑old man with a completely regressed metastatic melanoma who developed a second melanoma with concomitant involution of papillomatous nevi under BRAF inhibitors treatment. In reviewed literature we have found 53 cases of completely regressed primary melanomas, neither of them reporting nevi involution. Complete regression of primary tumor can occur as an immune response to tumor progression. Nevi can involute under BRAF inhibitor therapy, but development of new malignant lesions under BRAF inhibitors is linked to BRAF wild-type. Documentation of primary tumor and dynamic changes in nevi highlight the need of a good clinical skin examination and increase the utility of baseline and sequential dermoscopy in melanoma.

View Figures

View References

1	Mitchell JK and Leslie KS: Melanoma death prevention: Moving away from the sun. J Am Acad Dermatol. 68:e169–e175. 2013. View Article : Google Scholar : PubMed/NCBI
2	Neagu M, Caruntu C, Constantin C, Boda D, Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin carcinogenesis: Updates in experimental models (Review). Oncol Rep. 35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bastian BC: The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 9:239–271. 2014. View Article : Google Scholar : PubMed/NCBI
5	Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, : Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
6	Sullivan RJ: Molecular diagnostics and tumor mutational analysis. BRAF Targets in Melanoma-Biological Mechanisms. Resistance and Drug Discovery; Springer, New York, NY: pp. 47–72. 2015
7	Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S and Fernandez-Peñas P: Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 151:1103–1109. 2015. View Article : Google Scholar : PubMed/NCBI
8	Bolognia JL, Schaffer JV and Cerroni L: Neoplasms of the skin. Dermatology. 4th. Elsevier; pp. 1989–2020. 2018
9	Shai A, Avinoach I and Sagi A: Metastatic malignant melanoma with spontaneous and complete regression of the primary lesion. Case report and review of the literature. J Dermatol Surg Oncol. 20:342–345. 1994. View Article : Google Scholar : PubMed/NCBI
10	Ehrsam E, Kallini JR, Lebas D, Khachemoune A, Modiano P and Cotten H: Fully regressive melanoma: A case without metastasis. J Clin Aesthet Dermatol. 9:42–46. 2016.PubMed/NCBI
11	High WA, Stewart D, Wilbers CR, Cockerell CJ, Hoang MP and Fitzpatrick JE: Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: A report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol. 53:89–100. 2005. View Article : Google Scholar : PubMed/NCBI
12	Bories N, Dalle S, Debarbieux S, Balme B, Ronger-Savlé S and Thomas L: Dermoscopy of fully regressive cutaneous melanoma. Br J Dermatol. 158:1224–1229. 2008. View Article : Google Scholar : PubMed/NCBI
13	Dasgupta T, Bowden L and Berg JW: Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 117:341–345. 1963.PubMed/NCBI
14	Smith JL Jr and Stehlin JS Jr: Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 18:1399–1415. 1965. View Article : Google Scholar : PubMed/NCBI
15	Todd DW, Farrow GM, Winkelmann RK and Payne WS: Spontaneous regression of primary malignant melanoma with regional metastasis: Report of a case with photographic documentation. Mayo Clin Proc. 41:672–676. 1966.PubMed/NCBI
16	Milton CW, Lane Brown MM and Gilder M: Malignant melanoma with an occult primary lesion. Br J Surg. 54:651–658. 1967. View Article : Google Scholar : PubMed/NCBI
17	Cochran AJ, Diehl V and Stjernswärd J: Regression of primary malignant melanoma associated with a good prognosis despite metastasis to lymph nodes. Rev Eur Etud Clin Biol. 15:969–972. 1970.PubMed/NCBI
18	McGovern VJ: Spontaneous regression of melanoma. Pathology. 7:91–99. 1975. View Article : Google Scholar : PubMed/NCBI
19	MacDougal BA, Weeks PM and Wray RC Jr: Spontaneous regression of the primary lesion of a metastatic malignant melanoma. Plast Reconstr Surg. 57:355–358. 1976. View Article : Google Scholar : PubMed/NCBI
20	Whicker JH, DeMarco PR and Fitzgibbons JF: Spontaneous regression of a facial malignant melanoma. Arch Otolaryngol. 106:50–51. 1980. View Article : Google Scholar : PubMed/NCBI
21	Pellegrini AE: Regressed primary malignant melanoma with regional metastases. Arch Dermatol. 116:585–586. 1980. View Article : Google Scholar : PubMed/NCBI
22	Landthaler M and Braun-Falco O: Malignant melanoma with unknown primary tumor. Case reports of 12 patients with overview. Hautarzt. 32:339–344. 1981.(In German). PubMed/NCBI
23	Kessler E, Schwartz P and Antebi E: Spontaneous regression of primary malignant melanoma with metastases. Plast Reconstr Surg. 74:427–429. 1984. View Article : Google Scholar : PubMed/NCBI
24	Rampen FH and Meijer J: Metastatic melanoma of the brain after spontaneous regression of the primary. Acta Neurol Scand. 72:222–224. 1985. View Article : Google Scholar : PubMed/NCBI
25	Paul E and Müllhofer R: Metastasizing malignant melanoma from unknown primary tumor. Hautarzt. 41:432–437. 1990.(In German). PubMed/NCBI
26	Bottger D, Dowden RV and Kay PP: Complete spontaneous regression of cutaneous primary malignant melanoma. Plast Reconstr Surg. 89:548–553. 1992. View Article : Google Scholar : PubMed/NCBI
27	Avril MF, Charpentier P, Margulis A and Guillaume JC: Regression of primary melanoma with metastases. Cancer. 69:1377–1381. 1992. View Article : Google Scholar : PubMed/NCBI
28	Sais G, Marcoval J, Juggla A, Curco N and Servitje O: Dermatomyositis and metastatic malignant melanoma, with complete regression of the primary lesion. Br J Dermatol. 130:796–797. 1994. View Article : Google Scholar : PubMed/NCBI
29	Emanuel PO, Mannion M and Phelps RG: Complete regression of primary malignant melanoma. Am J Dermatopathol. 30:178–181. 2008. View Article : Google Scholar : PubMed/NCBI
30	Mărgăritescu I, Chiriţă AD and Vasilescu F: Completely regressed primary cutaneous melanoma - difficulties in diagnosis and classification. Rom J Morphol Embryol. 55 (Suppl 2):635–642. 2014.PubMed/NCBI
31	Yamada S, Nawata A, Yoshioka M, Hiraki T, Higashi M, Hatanaka K and Tanimoto A: Complete regression of primary cutaneous malignant melanoma associated with distant lymph node metastasis: A teaching case mimicking blue nevus. BMC Res Notes. 9:3662016. View Article : Google Scholar : PubMed/NCBI
32	Dunn GP, Lewis JS Jr, Sunwoo JB and Uppaluri R: Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia. Head Neck. 30:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
33	Menzies SW and McCarthy WH: Complete regression of primary cutaneous malignant melanoma. Arch Surg. 132:553–556. 1997. View Article : Google Scholar : PubMed/NCBI
34	Khosravi H, Akabane AL, Alloo A, Nazarian RM and Boland GM: Metastatic melanoma with spontaneous complete regression of a thick primary lesion. JAAD Case Rep. 2:439–441. 2016. View Article : Google Scholar : PubMed/NCBI
35	Martín JM, Pinazo I, Monteagudo C, Markovic J, Allende A and Jordá E: Spontaneous regression of multiple melanocytic nevi after melanoma: Report of 3 cases. Am J Dermatopathol. 36:e183–e188. 2014. View Article : Google Scholar : PubMed/NCBI
36	McClenahan P, Lin LL, Tan JM, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow TW, Sturm RA, et al: BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA Dermatol. 150:1079–1082. 2014. View Article : Google Scholar : PubMed/NCBI
37	Argenziano G, Zalaudek I, Corona R, Sera F, Cicale L, Petrillo G, Ruocco E, Hofmann-Wellenhof R and Soyer HP: Vascular structures in skin tumors: A dermoscopy study. Arch Dermatol. 140:1485–1489. 2004. View Article : Google Scholar : PubMed/NCBI
38	Zalaudek I, Argenziano G, Ferrara G, Soyer HP, Corona R, Sera F, Cerroni L, Carbone A, Chiominto A, Cicale L, et al: Clinically equivocal melanocytic skin lesions with features of regression: A dermoscopic-pathological study. Br J Dermatol. 150:64–71. 2004. View Article : Google Scholar : PubMed/NCBI
39	Pozzobon FC, Puig-Butillé JA, González-Alvarez T, Carrera C, Aguilera P, Alos L, Badenas C, Grichnik JM, Malvehy J and Puig S: Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma. Br J Dermatol. 171:754–759. 2014. View Article : Google Scholar : PubMed/NCBI
40	Massi G and LeBoit PE: Histological Diagnosis of Nevi and Melanoma. Springer; Berlin, Heidelberg: pp. 385–398. 2014
41	Cheng L, Lopez-Beltran A, Massari F, MacLennan GT and Montironi R: Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. Mod Pathol. 31:24–38. 2018. View Article : Google Scholar : PubMed/NCBI
42	Diaconeasa A, Boda D, Solovan C, Enescu DM, Vîlcea AM and Zurac S: Histopathologic features of Spitzoid lesions in different age groups. Rom J Morphol Embryol. 54:51–62. 2013.PubMed/NCBI
43	Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al: High frequency of BRAF mutations in nevi. Nat Genet. 33:19–20. 2003. View Article : Google Scholar : PubMed/NCBI
44	Haenssle HA, Kraus SL, Brehmer F, Kretschmer L, Völker B, Asper H, Kapp A and Gutzmer R: Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: Importance of sequential dermoscopy. Arch Dermatol. 148:1183–1185. 2012. View Article : Google Scholar : PubMed/NCBI
45	Weeraratna AT: RAF around the edges - the paradox of BRAF inhibitors. N Engl J Med. 366:271–273. 2012. View Article : Google Scholar : PubMed/NCBI
46	Aung PP, Nagarajan P and Prieto VG: Regression in primary cutaneous melanoma: Etiopathogenesis and clinical significance. Lab Invest. 97:657–668. 2017. View Article : Google Scholar
47	Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, et al: Neuroendocrine factors: The missing link in non-melanoma skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
48	Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endocrinol (Copenh). 10:545–558. 2014.
49	Boda D: Cellomics as integrative omics for cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar